Loss: improved to $1.8m from a $10.8m loss in the year prior
Main takeaway: Revenue rises from a low base as Rua seeks fresh funding.
NZX-listed medicinal cannabis company Rua Biosciences has reported a big revenue boost as it struggles to raise the funds it needs to stay in business.
While export changes last year made it easier for industry players to sell offshore, for many companies it came too late, with listed Greenfern
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
